Work

A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and/or locally advanced or metastatic hepatocellular carcinoma.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4217

Authors: Daneng Li, Neal Shiv Chawla, Andrea S. Teague, Koho Iizuka, Hong Tang, Varun N. Kapoor, Eric Cheung

Institutions: City Of Hope National Medical Center, City of Hope, Sarcoma Oncology Center, CHRISTUS St. Vincent Regional Cancer Center, Coherus BioSciences (United States), Los Alamitos Medical Center

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Coherus Biosciences

OpenAlex ID: W4410814287

FWCI: 0.497

Cites:

Cited by: 1

Related to: 10